Molecular tumor boards improve outcomes for patients with advanced cancer

by Elizabeth Chapin,University of KentuckyWaterfall plot detailing individual PFS ratio (PFS2/PFS1) values for patients treated with second-line or greater-line MTB-directed therapy (cohort 1; n

Updated on: December 22,2023

Molecular tumor boards improve outcomes for patients with advanced cancer

by Elizabeth Chapin,University of KentuckyWaterfall plot detailing individual PFS ratio (PFS2/PFS1) values for patients treated with second-line or greater-line MTB-directed therapy (cohort 1; n

Updated on:December 22,2023

Radiation therapy outcomes better for African-American than Caucasian prostate cancer patients

byAmerican Society for Radiation OncologyWhile popular beliefs and population data suggest that African-American men are at higher risk of dying from prostate cancer than Caucasian men, a new an

Updated on: December 18,2023

Radiation therapy outcomes better for African-American than Caucasian prostate cancer patients

byAmerican Society for Radiation OncologyWhile popular beliefs and population data suggest that African-American men are at higher risk of dying from prostate cancer than Caucasian men, a new an

Updated on:December 18,2023

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on: July 11,2024

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on:July 11,2024

Here's why some high-risk patients aren't getting drugs to combat COVID

by Emily Alpert Reyes, Los Angeles TimesCredit: Unsplash/CC0 Public DomainAs the toll from the COVID-19 pandemic continued to mount, antiviral medications such as Paxlovid were hailed by health offici

Updated on: May 26,2024

Here's why some high-risk patients aren't getting drugs to combat COVID

by Emily Alpert Reyes, Los Angeles TimesCredit: Unsplash/CC0 Public DomainAs the toll from the COVID-19 pandemic continued to mount, antiviral medications such as Paxlovid were hailed by health offici

Updated on:May 26,2024

6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return

by Peter Thorley,University of WarwickCredit: CC0 Public DomainA new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast

Updated on: March 14,2024

6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return

by Peter Thorley,University of WarwickCredit: CC0 Public DomainA new study co-led by the University of Warwick Clinical Trials Unit has shown that shortening the duration of a therapy for breast

Updated on:March 14,2024

Robotic resection cuts perioperative morbidity with liver cancer

by Lori SolomonRobotic liver resection (RLR) is associated with a significant reduction in perioperative morbidity for treatment of hepatocellular carcinoma (HCC) versus open-liver resection (OLR), ac

Updated on: December 25,2023

Robotic resection cuts perioperative morbidity with liver cancer

by Lori SolomonRobotic liver resection (RLR) is associated with a significant reduction in perioperative morbidity for treatment of hepatocellular carcinoma (HCC) versus open-liver resection (OLR), ac

Updated on:December 25,2023

Predicting prostate cancer recurrence 15 months sooner

by Steve Martin,Purdue UniversityGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.105430A Purdue University mechanical engineer and his international collaborators

Updated on: January 06,2024

Predicting prostate cancer recurrence 15 months sooner

by Steve Martin,Purdue UniversityGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.105430A Purdue University mechanical engineer and his international collaborators

Updated on:January 06,2024

Phase I clinical trial of the first drug to successfully inhibit the MYC gene that drives many common cancers

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainResearchers report that a drug targeting the cancer-causing gene MYC inhibits the function of the gene in

Updated on: December 20,2023

Phase I clinical trial of the first drug to successfully inhibit the MYC gene that drives many common cancers

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainResearchers report that a drug targeting the cancer-causing gene MYC inhibits the function of the gene in

Updated on:December 20,2023

Public insurance tied to lower cancer survival in young patients

(HealthDay)—Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online Dec. 1

Updated on: December 22,2023

Public insurance tied to lower cancer survival in young patients

(HealthDay)—Young, low-income patients with bone or soft tissue sarcomas have decreased overall survival (OS), regardless of disease stage at presentation, according to a study published online Dec. 1

Updated on:December 22,2023

Novel form of immunotherapy could revolutionize cancer treatment

by Noelle Toumey Reetz,Georgia State UniversityFig. 1: Local RT eliminates late-stage MC38 tumors in Sirpα−/− mice but not WT mice. From: Intratumoral SIRPα-deficient macrophages activate tumor

Updated on: March 25,2024

Novel form of immunotherapy could revolutionize cancer treatment

by Noelle Toumey Reetz,Georgia State UniversityFig. 1: Local RT eliminates late-stage MC38 tumors in Sirpα−/− mice but not WT mice. From: Intratumoral SIRPα-deficient macrophages activate tumor

Updated on:March 25,2024

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which

Updated on: July 17,2024

Trial of cell-based therapy for high-risk lymphoma leads to FDA breakthrough designation

by Krista Conger,Stanford UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDCAR-T cell therapy, which

Updated on:July 17,2024

Most cancer patients want access to complementary therapies before treatment

by The Reis GroupCredit: Pixabay/CC0 Public DomainNearly two-thirds (62%) of people with cancer want to know about complementary therapies such as exercise, nutrition counseling, massage, and meditati

Updated on: December 20,2023

Most cancer patients want access to complementary therapies before treatment

by The Reis GroupCredit: Pixabay/CC0 Public DomainNearly two-thirds (62%) of people with cancer want to know about complementary therapies such as exercise, nutrition counseling, massage, and meditati

Updated on:December 20,2023